drugset / Trial / NCT00848783
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.
Timeline
- Start
- 2008-05
- Primary completion
- 2011-08
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Floxuridine | Unknown | 3 g | Other |
| Background | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Background | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 75 mg/m2 | Intravenous |